Abra: What Is Still Open After the 2025 Acquisitions
Abra's 2025 acquisitions widened the platform, but they also left behind NIS 45.1 million of new goodwill, NIS 28.7 million of minority put liabilities, and an ownership structure that is still not fully rolled up. That means part of the value recorded in 2025 still depends on acquired-company performance, valuation models, and later buyouts.
What Is Still Open
The main article focused on whether 2025 marked a real return to growth for Abra, and on what was still missing before the funding picture could look cleaner. This follow-up isolates a different layer: what exactly remained unresolved after the 2025 acquisition wave, and how much of the value recorded this year still depends on future performance, valuation work, and later purchases from minorities.
Three points stand out immediately. Most of the consideration was not booked into identifiable net assets. The three 2025 acquisitions carried aggregate consideration of NIS 62.6 million, but only NIS 17.5 million of identifiable net assets came onto the balance sheet, while NIS 45.1 million was booked as goodwill. The bill also did not close in 2025. At year-end the balance sheet already carried NIS 28.7 million of liabilities for put options granted to non-controlling interests and another NIS 3.4 million of business-combination and contingent-consideration liabilities. The ownership ladder also remained incomplete. Methoda still had 9% in the hands of its CEO, CRG still had 45% in the hands of its managers, Medistat still had 40% held by the company owned by Medistat's CEO, and אברא צפון only received a deferral of the exercise timetable until after the 2027 financial statements.
These are not accounting footnotes. They define how much of the value that appeared in 2025 already belongs to shareholders, and how much still depends on whether the acquired companies deliver the earnings, cash flow, and exit terms that the agreements assume.
Where the Consideration Actually Landed
The right way to read the three 2025 acquisitions is not as three cash receipts that have already been paid and closed, but as three deals where only part of the bill was settled immediately. In note 21 all three business combinations are still presented on provisional amounts under the IFRS 3 measurement-period framework. In other words, the accounting allocation itself is not final yet, and the company retains a window of up to one year from the acquisition date to revise the numbers retrospectively if new information emerges.
That chart matters because it breaks the illusion that Abra simply spent NIS 62.6 million and received three businesses. Methoda closed with NIS 18.7 million of cash, NIS 473 thousand of payables, and a NIS 2.29 million put option. In CRG, cash was NIS 13.7 million, but the deal also left behind a NIS 5.77 million put option and NIS 1.66 million of non-controlling interests. In Medistat the layer is even more obvious: NIS 13.75 million of cash, NIS 1.49 million of additional and contingent consideration, a NIS 4.04 million put option, and NIS 777 thousand of non-controlling interests.
The most interesting detail is in Medistat. The deal terms state that on June 30, 2026 Abra is due to pay additional consideration equal to 25% of Medistat's audited 2025 net profit, plus contingent consideration of up to NIS 3 million subject to operating-profit targets. Part of the acquisition price therefore was not fixed at signing. It still depends on performance that Abra must now see in the audited numbers.
The ownership structure tells the same story. Methoda remained with 9% in the hands of its CEO, Yaniv Shoshani. In CRG, 45% stayed with the joint managers, while the option structure could still transfer another 25% to Abra. In Medistat, 40% stayed with the company owned by Medistat's CEO, alongside option mechanisms on another 20%. That may be a sensible alignment structure. It is also an admission that the value bought in 2025 is not fully closed yet.
The Balance Sheet Now Leans More on Goodwill
Note 10 gives the clearest picture of what 2025 really added to the balance sheet. The three acquisitions brought NIS 17.7 million of identifiable intangible assets into consolidation, but goodwill jumped by NIS 45.1 million and reached NIS 247.6 million at year-end 2025. Together with NIS 70.4 million of net intangible assets, that means NIS 318.0 million of intangible-heavy assets against total equity of NIS 366.5 million. Put differently, about 87% of year-end equity was already backed by goodwill and intangible assets.
What matters in that chart is not only that goodwill is large. It is that goodwill is the core of the deal structure. In aggregate, about 72% of the consideration across the three acquisitions was recorded as goodwill and only about 28% as identifiable net assets. That does not mean the acquisitions were bad. It does mean their value will have to be proven through profitability, cash generation, and synergies rather than through a clearly identifiable asset base that investors can already see on the balance sheet.
There is another point worth noticing. The company states that no goodwill impairment was recognized in 2023, 2024, or 2025. The impairment test is based on five-year cash-flow forecasts, discount rates ranging from 12.5% to 15.88%, and a terminal growth rate of 1.5%. That is a legitimate framework, but it is still a reminder that the largest line created by the 2025 deals rests on management assumptions about future cash generation.
The Ownership Ladder Is Still Incomplete
The balance sheet is not just a goodwill story. It is also a story of a minority layer that did not shrink, but rather grew. Liabilities for put options granted to non-controlling interests rose from NIS 22.0 million at the end of 2024 to NIS 28.7 million at the end of 2025, an increase of about 31%. Business-combination and contingent-consideration liabilities rose from NIS 1.1 million to NIS 3.4 million. Non-controlling interests themselves also rose from NIS 9.6 million to NIS 13.5 million.
This is a non-obvious point. In 2025 Abra did clean up some old structures, but it added new ones faster than it closed old ones. On August 14, 2025 it bought an additional 15% in אברא הטמעת מערכות מידע ארגוניות for gross consideration of NIS 8.307 million, including unpaid dividends, while offsetting NIS 4.320 million against the balance of a shareholder loan it had extended back in 2020. Even after that step, however, Abra still held only 80% there and retained only a call right on the remaining 20%. In other words, even when Abra closes one floor of the staircase, it does not necessarily close the whole staircase.
The same logic appears in several places:
| Company | What remains open | What happened in 2025 | What it means now |
|---|---|---|---|
| Methoda | 9% remained in the hands of CEO Yaniv Shoshani, with mutual put and call options | Abra rose to about 91% in June 2025 | The acquisition is not 100%, so future value capture is not fully closed |
| CRG | 45% remained with the joint managers | Abra bought control at about 55% and set a mechanism that could transfer another 25% | Control exists, but part of the economic value still sits with target management |
| Medistat | 40% remained with the company owned by Medistat's CEO | Additional consideration based on 2025 profit, contingent consideration of up to NIS 3 million, and options on another 20% were all embedded in the deal | This is the acquisition with the most active layer of future payments and performance dependence |
| אברא הטמעת מערכות מידע ארגוניות | 20% still remains outside the group | Abra bought another 15% and moved to 80% | Even after a meaningful payment and a loan offset, the ladder is still not fully closed |
| אברא צפון | Put and call options on another 20% were not cancelled, only deferred | The exercise timing was pushed to near the approval of the 2027 statements | The delay buys time, but it does not erase the potential obligation |
| אברא שירותי מחשוב | Only after year-end did another layer get bought | On January 1, 2026 Abra bought another 20% for NIS 550 thousand and moved to 80% | Even after a post-balance-sheet clean-up step, the group picture is still not one of full ownership everywhere |
The message in that table is straightforward: 2025 did not only add three new businesses. It also lengthened the list of places where Abra has operating control but does not yet hold all the economic value or all the future cash outflow exposure.
Why This Matters Now
The real meaning of 2025 is that Abra bought more than growth. It also bought an option on successful integration. If Methoda, CRG, and Medistat deliver profitability and cash flow, the goodwill will look reasonable, the minority layer can shrink over time, and the staged ownership model can be seen as a smart way to keep managers aligned. If that does not happen, the very same architecture turns from a growth anchor into another line of economic claims on the business.
The nearest checkpoint is Medistat. There, part of the consideration is supposed to be determined by audited 2025 profit and paid by June 30, 2026, while contingent consideration is also tied to operating-profit targets. That is the acquisition where the move from accounting thesis to real value should be tested first.
At the same time, the three 2025 acquisitions are still inside the IFRS 3 measurement period. That means the allocation between goodwill, identifiable assets, and liabilities can still move retrospectively. Anyone reading 2025 growth as if everything is already locked down misses the point: even the accounting numbers attached to those deals are not fully sealed yet.
That said, the risk still needs proportion. Even after the increase, minority put liabilities plus business-combination and contingent-consideration liabilities total about NIS 32.1 million, not an amount that by itself destabilizes a group with NIS 366.5 million of equity. So the immediate risk is less one of acute liquidity stress and more one of value quality: can Abra turn its goodwill-heavy, minority-layered structure into value that truly belongs to ordinary shareholders without having to pay for it again later.
That is the real unresolved question after the 2025 acquisitions: not whether Abra bought more revenue, but how much of the value recorded this year is already proven, already fully owned, and already backed by cash rather than by assumptions.